Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Melatonin for Cognition and Brain Health in Aging

Start: November 12, 2019
End: November 2025
Enrollment: 230

What Is This Study About?

Melatonin is a hormone involved in regulating sleep cycles that's also sold as an over-the-counter supplement. This clinical trial will examine whether melatonin can improve Alzheimer's disease biomarkers and cognitive function in older adults with and without mild cognitive impairment. Participants will be randomly assigned to take 5 mg of melatonin or a placebo pill 30 minutes before bedtime for nine months. Researchers will measure changes in memory and cognitive function, as well as levels of proteins in cerebrospinal fluid. Participants will also wear an actigraphy watch that measures cycles of activity and rest.

Do I Qualify To Participate in This Study?

Minimum Age: 56 Years

Maximum Age: 85 Years

Must have:

  • Montreal Cognitive Assessment score of 18 or above
  • Clinical Dementia Rating sum of boxes score less than 1
  • Willing to undergo lumbar puncture on three occasions
  • Able and willing to stop using any sleep aids, except study-issued medications. for the study duration
  • Body mass index less than 35
  • Study partner who knows participant well and can attend four visits

Must NOT have:

  • Obstructive sleep apnea, chronic obstructive pulmonary disease, or emphysema
  • Major psychiatric disease, such as bipolar or schizophrenia
  • History of alcohol or drug abuse
  • Diagnosis of neurodegenerative disease, including Parkinson's, Lewy body dementia, amyotrophic lateral sclerosis, and multiple sclerosis
  • History of stroke or traumatic brain injury
  • Chemotherapy in past 2 years
  • Hospitalized for injury or surgery in past 3 months
  • Significant depression/anxiety (score of 9 or more on the Geriatric Depression Scale or Geriatric Anxiety Inventory)
  • Prohibited medications: fluvoxamine, fluoxetine, nifedipine, anticoagulants (e.g., warfarin, heparin), antiseizure drugs, muscle relaxants, narcotic pain relievers (e.g., codeine, tramadol, hydrocodone)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Natalie Denburg, Ph.D

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

University of Iowa Hospitals & Clinics
Iowa City, IA 52242
Natalie Denburg, Ph.D.

Who Sponsors This Study?

Lead: Nazan Aksan

Source: ID: NCT03954899

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health